• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Exact Sciences Named 2025 Gallup Exceptional Workplace Award Winner

    3/12/25 9:00:00 AM ET
    $EXAS
    Medical Specialities
    Health Care
    Get the next $EXAS alert in real time by email

    Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has received the 2025 Gallup Exceptional Workplace Award (GEWA), marking the second year in a row the company has received this prestigious recognition. This award recognizes the most engaged workplace cultures in the world.

    Gallup created the Exceptional Workplace Award to identify excellence and celebrate organizations that incorporate employee engagement into the bedrock of how they do their work, motivate their teams, and achieve business outcomes.

    "Exact Sciences' success starts with our people, and winning the Gallup Exceptional Workplace Award for the second consecutive year is a testament to the dedication of our incredible team," said Sarah Condella, executive vice president of human resources at Exact Sciences. "Our culture is built on shared values, collaboration, and a relentless commitment to our mission. By fostering an environment where employees feel engaged, supported, and empowered, we continue to make a meaningful impact on patients and advance our fight against cancer."

    The GEWA winners' ratio of engaged employees to actively disengaged employees is 11 times higher than the global average. Worldwide, only 23% of employees are engaged — that is, committed to their work and connected to their workplace — and just 33% of employees in the U.S. workforce are engaged. Seventy percent of employees at winning GEWA organizations are engaged.

    "Congratulations to this year's Gallup Exceptional Workplace Award winners for setting the standard for a thriving workplace. Your commitment to creating an environment where employees feel valued, heard and empowered to do their best work is truly remarkable. By prioritizing both people and performance, you are shaping the future of work and proving that exceptional workplaces drive real results," said Jon Clifton, Gallup's chief executive officer.

    Gallup's meta-analysis on team engagement and performance is the most comprehensive workplace study ever conducted, with data on more than 3.3 million employees in 347 organizations across 53 industries and 90 countries. The company's research shows that highly engaged organizations significantly outperform their peers in important business outcomes, including customer ratings, profitability, productivity, turnover, safety incidents, shrinkage, absenteeism, quality, well-being, and organizational citizenship.

    For a complete list of GEWA winners and more about the selection process, visit the winners page.

    Exact Sciences is looking for talented people who are passionate about helping patients and fighting cancer. For more information and to view a complete list of job openings, visit the company's careers site.

    About Exact Sciences Corp.

    A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X (formerly known as Twitter) @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.

    About Gallup

    Gallup delivers analytics and advice to help leaders and organizations solve their most pressing problems. Combining more than 80 years of experience with its global reach, Gallup knows more about the attitudes and behaviors of employees, customers, students, and citizens than any other organization in the world.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250312984942/en/

    Exact Sciences

    Blair Brophy

    [email protected]

    608-630-7391

    Gallup

    [email protected]

    Get the next $EXAS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EXAS

    DatePrice TargetRatingAnalyst
    1/20/2026$105.00Outperform → Neutral
    Mizuho
    1/5/2026$105.00Outperform → In-line
    Evercore ISI
    4/10/2025$60.00Outperform
    Mizuho
    3/13/2025$52.00Sector Perform
    RBC Capital Mkts
    1/23/2025$70.00Overweight
    Barclays
    8/28/2024$75.00Overweight
    Wells Fargo
    6/27/2024$70.00Sector Outperform
    Scotiabank
    6/3/2024$75.00Buy
    Jefferies
    More analyst ratings

    $EXAS
    SEC Filings

    View All

    SEC Form DEFA14A filed by Exact Sciences Corporation

    DEFA14A - EXACT SCIENCES CORP (0001124140) (Filer)

    1/30/26 4:01:09 PM ET
    $EXAS
    Medical Specialities
    Health Care

    SEC Form DEFA14A filed by Exact Sciences Corporation

    DEFA14A - EXACT SCIENCES CORP (0001124140) (Filer)

    1/23/26 6:03:01 AM ET
    $EXAS
    Medical Specialities
    Health Care

    SEC Form DEFM14A filed by Exact Sciences Corporation

    DEFM14A - EXACT SCIENCES CORP (0001124140) (Filer)

    1/9/26 8:15:20 AM ET
    $EXAS
    Medical Specialities
    Health Care

    $EXAS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Exact Sciences downgraded by Mizuho with a new price target

    Mizuho downgraded Exact Sciences from Outperform to Neutral and set a new price target of $105.00

    1/20/26 9:08:04 AM ET
    $EXAS
    Medical Specialities
    Health Care

    Exact Sciences downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Exact Sciences from Outperform to In-line and set a new price target of $105.00

    1/5/26 8:47:19 AM ET
    $EXAS
    Medical Specialities
    Health Care

    Mizuho initiated coverage on Exact Sciences with a new price target

    Mizuho initiated coverage of Exact Sciences with a rating of Outperform and set a new price target of $60.00

    4/10/25 12:41:36 PM ET
    $EXAS
    Medical Specialities
    Health Care

    $EXAS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, GM, Screening Orville Jacob A converted options into 73,080 shares, covered exercise/tax liability with 68,437 shares and was granted 72,523 shares, increasing direct ownership by 332% to 100,403 units (SEC Form 4)

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    12/30/25 4:30:14 PM ET
    $EXAS
    Medical Specialities
    Health Care

    EVP, GM, Precision Oncology Baranick Brian converted options into 73,080 shares, covered exercise/tax liability with 84,097 shares and was granted 92,523 shares, increasing direct ownership by 364% to 103,874 units (SEC Form 4)

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    12/30/25 4:30:12 PM ET
    $EXAS
    Medical Specialities
    Health Care

    EVP, Human Resources Condella Sarah converted options into 47,208 shares, covered exercise/tax liability with 41,938 shares and was granted 42,018 shares, increasing direct ownership by 58% to 129,134 units (SEC Form 4)

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    12/30/25 4:30:09 PM ET
    $EXAS
    Medical Specialities
    Health Care

    $EXAS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Exact Sciences Applauds Passage of Legislation Establishing Medicare Coverage Pathway for Multi-Cancer Early Detection Tests

    Passage of MCED legislation marks major milestone for early cancer detection Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today celebrated the passage of landmark federal legislation that establishes a pathway to enable Medicare coverage for multi-cancer early detection (MCED) tests. Nearly 70% of annual cancer cases and deaths in the U.S. occur in cancers with no recommended screening,1,2 and cancer remains the second leading cause of death in the U.S.1 By aligning public policy with scientific innovation and patient need, this legislation represents a critical step toward addressing that unmet need and expanding access to this emerging

    2/3/26 2:32:00 PM ET
    $EXAS
    Medical Specialities
    Health Care

    Oncotype DX Breast Recurrence Score® Test Surpasses 2 Million Patients Worldwide

    Milestone underscores test's significant role as a global standard-of-care in guiding personalized breast cancer treatment The predictive utility of this test helped an estimated 1.6 million patients safely avoid potentially unnecessary chemotherapy Economic models demonstrate improved outcomes and the potential for U.S. system-wide cost savings Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced a significant milestone for its flagship Oncotype DX Breast Recurrence Score® test: more than two million breast cancer patients worldwide have now used the test to help guide treatment decisions. Backed by more than two decades of

    2/3/26 9:03:00 AM ET
    $EXAS
    Medical Specialities
    Health Care

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    $EXAS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Conroy Kevin T bought $1,001,325 worth of shares (19,500 units at $51.35), increasing direct ownership by 2% to 1,074,191 units (SEC Form 4)

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    11/13/24 12:56:28 PM ET
    $EXAS
    Medical Specialities
    Health Care

    $EXAS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Exact Sciences Corporation

    SC 13G - EXACT SCIENCES CORP (0001124140) (Subject)

    11/13/24 2:58:53 PM ET
    $EXAS
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Exact Sciences Corporation

    SC 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)

    11/8/24 10:52:39 AM ET
    $EXAS
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Exact Sciences Corporation

    SC 13G - EXACT SCIENCES CORP (0001124140) (Subject)

    10/7/24 11:37:08 AM ET
    $EXAS
    Medical Specialities
    Health Care

    $EXAS
    Leadership Updates

    Live Leadership Updates

    View All

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

    SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same

    3/19/25 4:10:00 PM ET
    $EXAS
    $QTRX
    $SERA
    Medical Specialities
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EXAS
    Financials

    Live finance-specific insights

    View All

    Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments

    Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segmentsAcquisition will uniquely position Abbott to transform cancer care, advancing earlier detection and optimizing treatment and monitoring to help millions more people live healthier livesExact Sciences' product lines feature advanced cancer screening and diagnostic solutions, including the market-leading Cologuard® and Oncotype DX® tests, and cutting-edge liquid biopsy tests for multi-cancer early detection and molecular residual disease testingAcquisition will be immediately accretive to

    11/20/25 7:30:00 AM ET
    $ABT
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    Exact Sciences Announces Third Quarter 2025 Results

    Reports record revenue, raises full-year guidance, generates record cash from operations Third quarter and recent highlights Delivered record total third quarter revenue of $851 million, an increase of 20% on a reported and core revenue basis, including Screening revenue of $666 million and Precision Oncology revenue of $184 million Raised full-year 2025 revenue and adjusted EBITDA guidance midpoints by $78 million and $10 million, respectively Generated record cash from operations and free cash flow Launched Cancerguard®, the company's multi-cancer early detection test, for patients in the United States Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer scree

    11/3/25 4:05:00 PM ET
    $EXAS
    Medical Specialities
    Health Care

    Exact Sciences Schedules Third Quarter 2025 Earnings Call

    Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2025 financial results after the close of the U.S. financial markets on November 3, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Third quarter 2025 webcast & conference call details Date: Monday, November 3, 2025 Time: 5 p.m. ET Webcast: The live webcast can be accessed at www.exactsciences.com Telephone: Domestic callers, dial 888-330-2384 International callers

    10/8/25 7:00:00 AM ET
    $EXAS
    Medical Specialities
    Health Care